Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative PRRT in Metastatic GEP-NETs
NCT04609592Phase 1Active, not recruiting
- Sponsor
- Stanford University
- Start
- Mar 2021
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Stanford University. Primary endpoint: Complication free Surgery at 6 months. Started Mar 2021; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04609592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609592.